supp.fit

Sarcosine: study protocols

14 study groups say how much Sarcosine participants took a day. These are the doses the studies gave. They are not a recommendation.

Sarcosine: what the research found →

Dose per serving from research

13 study groups in 11 studies say how much Sarcosine participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 1 g to 2.5 g, 92% of 13 study groups.

Daily doseStudy groups
1 g or less
1
1 g to 2.5 g
12

Commonly used together

1 of 14 study groups took Sarcosine with something else, but nothing that 3 or more different studies gave.

14 study groups

Study
Sarcosine treatment for oppositional defiant disorder symptoms of attention deficit hyperactivity disorder children
2016 · sarcosine recipients · Children with ADHD
30 mg/kg6 weeks58
Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia
2004 · sarcosine · patients with schizophrenia receiving stable antipsychotic regimens
2 g6 weeks—
Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study
2005 · sarcosine group · Inpatients with acute exacerbation of schizophrenia
2 g6 weeks—
Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study
2008 · 2-g group · Drug-free adults with acute schizophrenia; age and sex not reported
2 g6 weeks—
Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study
2008 · 1-g group · Drug-free adults with acute schizophrenia; age and sex not reported
1 g6 weeks—
A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia
2010 · Sarcosine · People with chronic schizophrenia; age and sex not specified
2 g6 weeks—
Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: A randomised, double-blind, placebo-controlled trial
2017 · sarcosine · chronic schizophrenia patients with constant clinical symptoms; age and sex not reported
2 g12 weeks—
Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: A randomised, double-blind, placebo-controlled trial
2017 · sarcosine plus benzoate · chronic schizophrenia patients with constant clinical symptoms; age and sex not reported
2 g12 weeks—
MMP-9 Serum Levels in Schizophrenic Patients during Treatment Augmentation with Sarcosine (Results of the PULSAR Study)
2016 · sarcosine group · Adults aged 18–60 with paranoid schizophrenia and dominant negative symptoms, on stable antipsychotic treatment
2 g26 weeks30
Serum levels of interleukin 6 in schizophrenic patients during treatment augmentation with sarcosine (results of the PULSAR study)
2018 · sarcosine · Patients with schizophrenia and predominantly negative symptoms
2 g26 weeks29
Serum levels of neuropeptide Y in patients with chronic schizophrenia during treatment augmentation with sarcosine (results of the double-blind randomized controlled PULSAR study)
2021 · sarcosine · People with chronic schizophrenia, predominant negative symptoms, and stable antipsychotic treatment
2 g26 weeks28
BDNF serum levels in schizophrenic patients during treatment augmentation with sarcosine (results of the PULSAR study)
2016 · sarcosine · People with schizophrenia with predominantly negative symptoms
2 g26 weeks27
Adding Sarcosine to Antipsychotic Treatment in Patients with Stable Schizophrenia Changes the Concentrations of Neuronal and Glial Metabolites in the Left Dorsolateral Prefrontal Cortex
2015 · Sarcosine group · Adults aged 18–60 with stable schizophrenia and dominant negative symptoms
2 g26 weeks25
Supplementation of Antipsychotic Treatment with the Amino Acid Sarcosine Influences Proton Magnetic Resonance Spectroscopy Parameters in Left Frontal White Matter in Patients with Schizophrenia
2015 · Sarcosine · Adults aged 18–60 with stable schizophrenia and dominant negative symptoms
2 g26 weeks25